Cambridge, MA-based Genzyme (NASDAQ:GENZ), the biotech powerhouse besieged by manufacturing problems, says its board has nominated former Amgen executive Dennis Fenton to its board of directors. Fenton, 58, developed significant biotech drug manufacturing expertise during his 25-year tenure at Thousand Oaks, CA-based biotech giant Amgen (NASDAQ:AMGN), according to Genzyme. He was executive vice president of operations at Amgen when he retired in 2008. Genzyme now has 10 members of its board, and all ten members are up for reelection at the firm’s annual meeting on June 16. Genzyme says that its board is expected to vote to expand the number of seats on the board to 11, and then vote to elect Fenton to the board after the annual meeting. Billionaire investor Carl Icahn is vying for four of the 10 seats up for reelection at the annual meeting next week.